Articles published by GlobeNewswire
Postal Realty to Participate in the NobleCon21 Conference & Nareit’s REITworld: 2025 Annual Conference
December 02, 2025
Via GlobeNewswire
Tickers
PSTL
CERo Therapeutics Announces Trading on OTCQB Market
December 02, 2025
Via GlobeNewswire
Tickers
CERO
Saia Provides Fourth Quarter LTL Operating Data
December 02, 2025
From Saia, Inc.
Via GlobeNewswire
Tickers
SAIA
Nkarta to Participate in Evercore Healthcare Conference
December 02, 2025
From Nkarta, Inc.
Via GlobeNewswire
Tickers
NKTX
Ventyx Provides Clinical and Corporate Updates
December 02, 2025
Via GlobeNewswire
Tickers
VTYX
Aeluma to Participate in Northland Growth Conference
December 02, 2025
From Aeluma, Inc.
Via GlobeNewswire
Tickers
ALMU
Stewards Inc. Appoints Scott McGowan as Chief Marketing Officer
December 02, 2025
From Stewards Inc.
Via GlobeNewswire
Tickers
SWRD
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
December 02, 2025
Via GlobeNewswire
Tickers
OVID
Via GlobeNewswire
Tickers
TLSA
Bitget Wallet Adds Rupee-to-Stablecoin Conversion via USDT Marketplace
December 02, 2025
From Bitget Limited
Via GlobeNewswire
NIP Group Inc. Reports First Half 2025 Unaudited Financial Results
December 02, 2025
From NIP GROUP INC.
Via GlobeNewswire
Tickers
NIPG
Wealthfront Announces Launch of Initial Public Offering
December 02, 2025
Via GlobeNewswire
Via GlobeNewswire
Tickers
BC
Via GlobeNewswire
Tickers
BC
Here Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2026
December 02, 2025
From Here Group Limited
Via GlobeNewswire
Tickers
HERE
Via GlobeNewswire
Tacalyx Appoints Jean Engela as Chief Executive Officer to Spearhead Next Phase of Growth
December 02, 2025
From Tacalyx GmbH
Via GlobeNewswire
Joveo Unveils AI Staffing Advisor: The Industry’s First Staffing Superintelligence Platform
December 02, 2025
From Joveo, Inc
Via GlobeNewswire
Bitget Supports Grassroots Football at LALIGA Youth Tournament in Manila
December 02, 2025
From Bitget Limited
Via GlobeNewswire
Enterome OncoMimics™ immunotherapy EO2401 shows survival benefit in Phase 2 glioblastoma trial
December 02, 2025
From Enterome
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
